181 related articles for article (PubMed ID: 31429371)
1. Brentuximab vedotin in relapsed or refractory classical hodgkin lymphoma: real life experience in Norway 2011-2016.
Fosså A; Smeland K; Fagerli UM; Galleberg RB; Bersvendsen HS; Holte H
Acta Oncol; 2020 Jan; 59(1):101-105. PubMed ID: 31429371
[No Abstract] [Full Text] [Related]
2. Successful salvage of primary progressive Hodgkin lymphoma with the combination of post-transplant brentuximab vedotin and radiotherapy: Combining novelty and tradition.
Belia M; Chatzidimitriou C; Rondogianni P; Petsa P; Efstathopoulou M; Konstantinou E; Arapaki M; Asimakopoulos J; Plata E; Konstantopoulos K; Angelopoulou MK; Vassilakopoulos TP
Hematol Oncol; 2021 Apr; 39(2):258-262. PubMed ID: 32905619
[No Abstract] [Full Text] [Related]
3. Three-year outcomes with brentuximab vedotin plus bendamustine as first salvage therapy in relapsed or refractory Hodgkin lymphoma.
LaCasce AS; Bociek RG; Sawas A; Caimi P; Agura E; Matous J; Ansell SM; Crosswell HE; Islas-Ohlmayer M; Behler C; Cheung E; Forero-Torres A; Vose J; O'Connor OA; Josephson N; Wang Y; Advani R
Br J Haematol; 2020 May; 189(3):e86-e90. PubMed ID: 32048731
[No Abstract] [Full Text] [Related]
4. A targeted salvage therapy with Brentuximab vedotin in heavily treated refractory or relapsed pediatric Hodgkin lymphoma patients before and after stem cell transplantation.
Taçyıldız N; Tanyıldız HG; Ünal E; Dinçaslan H; Asarcıklı F; Aksoy BA; Vatansever G; Yavuz G
Turk J Pediatr; 2019; 61(5):671-676. PubMed ID: 32104998
[TBL] [Abstract][Full Text] [Related]
5. Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1/2 trial.
Diefenbach CS; Hong F; Ambinder RF; Cohen JB; Robertson MJ; David KA; Advani RH; Fenske TS; Barta SK; Palmisiano ND; Svoboda J; Morgan DS; Karmali R; Sharon E; Streicher H; Kahl BS; Ansell SM
Lancet Haematol; 2020 Sep; 7(9):e660-e670. PubMed ID: 32853585
[TBL] [Abstract][Full Text] [Related]
6. Brentuximab Vedotin as Consolidation Therapy After Autologous Stem Cell Transplantation in Children and Adolescents (<18 y) With Early Relapse Hodgkin Lymphoma.
Fernández KS; Mavers M; Marks LJ; Agarwal R
J Pediatr Hematol Oncol; 2021 Mar; 43(2):e191-e194. PubMed ID: 31876780
[TBL] [Abstract][Full Text] [Related]
7. Brentuximab vedotin consolidation after autologous stem cell transplantation for Hodgkin lymphoma: A Fondazione Italiana Linfomi real-life experience.
Massaro F; Pavone V; Stefani PM; Botto B; Pulsoni A; Patti C; Cantonetti M; Visentin A; Scalzulli PR; Rossi A; Galimberti S; Cimminiello M; Gini G; Musso M; Sorio M; Arcari A; Zilioli VR; Luppi M; Mannina D; Fabbri A; Pietrantuono G; Annibali O; Tafuri A; Prete E; Mulè A; Barbolini E; Marcheselli L; Luminari S; Merli F
Hematol Oncol; 2022 Feb; 40(1):31-39. PubMed ID: 34694649
[TBL] [Abstract][Full Text] [Related]
8. Nivolumab for the treatment of relapsed and refractory classical Hodgkin lymphoma after ASCT and in ASCT-naïve patients.
Lepik KV; Mikhailova NB; Moiseev IS; Kondakova EV; Tsvetkova LA; Zalyalov YR; Borzenkova ES; Babenko EV; Baykov VV; Markova IV; Afanasyev BV
Leuk Lymphoma; 2019 Sep; 60(9):2316-2319. PubMed ID: 30712423
[No Abstract] [Full Text] [Related]
9. Brentuximab vedotin as consolidation after hematopoietic cell transplant for relapsed Hodgkin lymphoma in pediatric patients.
Flerlage JE; von Buttlar X; Krasin M; Triplett B; Kaste SC; Metzger ML
Pediatr Blood Cancer; 2019 Dec; 66(12):e27962. PubMed ID: 31429511
[No Abstract] [Full Text] [Related]
10. Hematopoietic Stem Cell Transplantation and Brentuximab Vedotin for Patients with Relapsed or Refractory Hodgkin Lymphoma and Systemic Anaplastic Large-Cell Lymphoma.
Ishizawa K; Yanai T
Adv Ther; 2019 Oct; 36(10):2679-2696. PubMed ID: 31392578
[TBL] [Abstract][Full Text] [Related]
11. Brentuximab vedotin and its use in the treatment of advanced Hodgkin's lymphoma.
Nikolaenko L; Nademanee A
Future Oncol; 2020 Oct; 16(29):2273-2282. PubMed ID: 32677451
[TBL] [Abstract][Full Text] [Related]
12. Results of a Multicenter Phase II Trial of Brentuximab Vedotin as Second-Line Therapy before Autologous Transplantation in Relapsed/Refractory Hodgkin Lymphoma.
Chen R; Palmer JM; Martin P; Tsai N; Kim Y; Chen BT; Popplewell L; Siddiqi T; Thomas SH; Mott M; Sahebi F; Armenian S; Leonard J; Nademanee A; Forman SJ
Biol Blood Marrow Transplant; 2015 Dec; 21(12):2136-2140. PubMed ID: 26211987
[TBL] [Abstract][Full Text] [Related]
13. Brentuximab vedotin for the treatment of patients with relapsed or refractory Hodgkin lymphoma after autologous stem cell transplantation.
Kaloyannidis P; Hertzberg M; Webb K; Zomas A; Schrover R; Hurst M; Jacob I; Nikoglou T; Connors JM
Br J Haematol; 2020 Feb; 188(4):540-549. PubMed ID: 31588564
[TBL] [Abstract][Full Text] [Related]
14. Brentuximab vedotin monotherapy is an effective treatment in a frail pediatric patient with Down syndrome and classical Hodgkin lymphoma.
Vonasek J; Edslev PW; d'Amore F; Hasle H
Pediatr Blood Cancer; 2020 Feb; 67(2):e28082. PubMed ID: 31724794
[No Abstract] [Full Text] [Related]
15. Relapsed classic Hodgkin lymphoma with decreased CD30 expression after brentuximab and anti-CD30 CAR-T therapies.
Kim DH; Vega F
Blood; 2022 Feb; 139(6):951. PubMed ID: 35142847
[No Abstract] [Full Text] [Related]
16. Hope After Salvage Therapy Fails: Novel Agents for Relapsed/Refractory Hodgkin Lymphoma.
Kallam A; Vose JM
Oncology (Williston Park); 2019 May; 33(5):192-8. PubMed ID: 31095720
[TBL] [Abstract][Full Text] [Related]
17. Successful reversal of severe liver function impairment with Brentuximab vedotin in multiply relapsed/refractory classical Hodgkin lymphoma.
Spathas N; Belia M; Giannikos T; Arapaki M; Efstathopoulou M; Tsourouflis G; Gainaru G; Asimakopoulos J; Tsaftaridis P; K Angelopoulou M; Plata E; Konstantopoulos K; P Vassilakopoulos T
J BUON; 2019; 24(6):2483-2489. PubMed ID: 31983123
[TBL] [Abstract][Full Text] [Related]
18. Long-term results of brentuximab vedotin in relapsed and refractory Hodgkin lymphoma: multi-center real-life experience.
Özbalak M; Salihoğlu A; Soysal T; Karadoğan İ; Paydaş S; Özdemir E; Yıldız B; Karadurmuş N; Kaynar L; Yagci M; Özkocaman V; Topçuoğlu P; Özcan M; Birtaş E; Göker H; Ferhanoglu B
Ann Hematol; 2020 Feb; 99(2):301-307. PubMed ID: 31844933
[TBL] [Abstract][Full Text] [Related]
19. Double-refractory Hodgkin lymphoma: tackling relapse after brentuximab vedotin and checkpoint inhibitors.
Epperla N; Hamadani M
Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):247-253. PubMed ID: 34889401
[TBL] [Abstract][Full Text] [Related]
20. Emerging Therapies in Relapsed and Refractory Hodgkin Lymphoma: What Comes Next After Brentuximab Vedotin and PD-1 Inhibition?
Othman T; Herrera A; Mei M
Curr Hematol Malig Rep; 2021 Feb; 16(1):1-7. PubMed ID: 33409966
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]